G
About
Iktos is a pioneering drug discovery company that integrates cutting-edge generative AI, automated retrosynthesis, and robotic lab automation into a unified platform. At its core are two SaaS products: Makya, a generative AI platform purpose-built by chemists for de novo drug design, and Spaya, an AI-driven retrosynthesis engine that identifies optimal synthetic routes in real time. Makya generates diverse, novel, and medchem-like small molecules with a focus on synthetic accessibility, multi-parametric optimization, and 3D structural constraints. Spaya complements this by rapidly converting target compounds into commercially viable synthetic routes, customizable to specific lab constraints and integrated with external data providers. Beyond software, Iktos Robotics provides a fully autonomous laboratory capable of managing synthesis workflows end-to-end — from ordering raw materials to executing chemical synthesis, purification, and multidimensional biological screening. This closed-loop Design-Make-Test-Analyze (DMTA) cycle drastically shortens the drug discovery timeline to under 24 months. Iktos also leverages high-content imaging for biological data generation, enabling identification of small-molecule modulators for challenging targets including protein-protein interactions, RNA-protein interactions, molecular glues, and PROTACs. The company operates its own internal pipeline across therapeutic areas such as inflammation, autoimmune diseases, and metabolic disorders. Iktos is ideal for pharmaceutical and biotech organizations seeking to accelerate hit discovery, hit-to-lead, and lead optimization programs with AI-driven precision.
Key Features
- Makya – Generative AI Molecule Design: A SaaS platform that generates novel, medchem-like small molecules using generative AI with multi-parametric optimization, synthetic accessibility filters, and 3D structural constraints.
- Spaya – AI-Driven Retrosynthesis: Identifies the most feasible synthetic routes in real time, converting target compounds into commercially available starting materials with customizable constraints and data provider integrations.
- Autonomous Robotic Lab: Fully automated laboratory system that handles synthesis workflow management, raw material ordering, chemical synthesis execution, purification, and multidimensional biological analysis.
- Closed-Loop DMTA Cycle: Integrates design, synthesis, testing, and analysis into a continuous AI-guided iteration loop that shortens the path from molecule inception to preclinical candidate to under two years.
- Multidimensional Biological Screening: High-content imaging and in-cellulo screening for challenging targets including protein-protein interactions, RNA-protein interactions, molecular glues, and PROTACs.
Use Cases
- Pharmaceutical companies accelerating hit-to-lead and lead optimization campaigns for small-molecule drug candidates using generative AI-designed compounds.
- Biotech startups compressing early-stage drug discovery timelines by leveraging Iktos's integrated DMTA cycle to reach preclinical candidates in under two years.
- Drug discovery teams using Spaya to rapidly identify feasible synthetic routes and reduce the time spent on manual retrosynthesis planning.
- Research organizations tackling hard-to-drug targets such as protein-protein interactions or RNA-protein interactions using Iktos's high-content biological screening platform.
- Medicinal chemists using Makya to generate novel, synthetically accessible molecule libraries optimized against multi-parametric drug-likeness and 3D structural criteria.
Pros
- End-to-End Drug Discovery Integration: Uniquely combines AI-driven molecular design, retrosynthesis planning, and robotic lab automation into one cohesive platform, eliminating handoff delays between discovery stages.
- Dramatically Reduced Timelines: The integrated AI-robotics approach compresses the drug discovery phase to under 24 months, offering a significant competitive advantage for pharma and biotech organizations.
- Designed by Chemists for Chemists: Makya's chemistry-driven approach ensures generated molecules are not only novel but synthetically feasible, bridging the gap between AI creativity and real-world chemistry.
- Tackles Hard-to-Drug Targets: Specialized biological screening capabilities address challenging modalities like protein-protein interactions, molecular glues, and PROTACs that traditional methods struggle with.
Cons
- Enterprise-Only Pricing: Iktos is positioned as an enterprise solution with no self-serve or free tier, making it inaccessible to individual researchers or small academic labs with limited budgets.
- Highly Specialized Use Case: The platform is purpose-built for small-molecule pharmaceutical drug discovery, limiting its utility outside this specific domain.
- Full Value Requires Robotics Infrastructure: The closed-loop DMTA cycle and autonomous lab features may require significant infrastructure investment or partnership with Iktos, adding operational complexity.
Frequently Asked Questions
What is Makya and how does it work?
Makya is Iktos's generative AI SaaS platform for de novo drug design. It uses generative AI technology to create diverse, novel, synthetically accessible small molecules, optimized across multiple parameters including 3D structural constraints — all designed with a chemistry-first approach.
What is Spaya and how is it different from Makya?
Spaya is Iktos's AI-driven retrosynthesis platform. While Makya designs new molecules, Spaya plans how to synthesize them by identifying optimal synthetic routes from target compounds back to commercially available starting materials in real time.
How does Iktos shorten drug discovery timelines?
Iktos integrates generative molecule design (Makya), retrosynthesis planning (Spaya), and a fully autonomous robotic lab into a closed-loop DMTA (Design-Make-Test-Analyze) cycle. This eliminates bottlenecks between stages and compresses discovery timelines to under 24 months.
What types of targets can Iktos's platform address?
Iktos is capable of targeting protein-protein interactions, RNA-protein interactions, protein self-assembly, molecular glues, and PROTACs — including many traditionally undruggable or difficult targets — using its multidimensional biological screening capabilities.
Does Iktos offer collaboration or partnership programs?
Yes, Iktos offers discovery collaborations in addition to its SaaS products. Pharma and biotech companies can partner with Iktos to leverage its full AI-robotics platform for specific drug discovery programs, or access Makya and Spaya independently as software tools.
